Peptide questions · Bofanglutide
Bofanglutide side effects: what studies and users report
Reviewed Evidence: ModeratePublished by PepVault
The side effects most commonly reported for bofanglutide are nausea, vomiting and diarrhea, among 4 the library lists; the library’s evidence on it includes controlled trials in people.
Its safety note opens: bofanglutide has no label: it is still in trials.
What is commonly reported with bofanglutide
- Nausea
- Vomiting
- Diarrhea
- Decreased appetite
Common here means the library lists it among the effects people most often report; the list doesn’t say how often each one happens.
| Effect | Also listed for (of 28) |
|---|---|
| Nausea | 24: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 20 more |
| Vomiting | 20: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 16 more |
| Diarrhea | 23: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 19 more |
| Decreased appetite | 10: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 6 more |

Model. Individual results vary.
Which bofanglutide side effects the metabolic & GLP-1 group shares
Across the 29 metabolic & GLP-1 compounds in the library, the effects listed most often are nausea (25 of 29), diarrhea (24 of 29), vomiting (21 of 29) and constipation (15 of 29). Every effect on bofanglutide’s list also appears for at least one other metabolic & GLP-1 compound, so nothing on it is bofanglutide’s own.
What the bofanglutide safety notes say
The library’s safety note
Bofanglutide has no label: it is still in trials. In the 30-week phase 2b trial, GI side effects (nausea, vomiting, diarrhea) affected 79% to 91% on bofanglutide vs 33% on placebo, mostly grade 1 to 2 and early in the step-ups; they were highest in the 48 mg group, which took bigger dose jumps, and adding in-between steps lowered them. In phase 3 the safety profile matched other GLP-1 drugs, with mostly mild to moderate, transient GI events and no new safety signals. It is a GLP-1 drug, so the class warnings in GLP-1 labels (including pancreatitis, gallbladder disease and the rodent thyroid C-cell finding) are the ones to read. These are trial findings to review with your clinician.
The library’s interaction note
No interaction results have been published; Gan & Lee has run studies of its effect on stomach emptying and on other drugs (NCT07128888) and on metformin (NCT06670209). GLP-1 drugs slow stomach emptying, which can change how oral medicines are absorbed. It is a GLP-1 drug itself, so it is not stacked with another one. With insulin or a sulfonylurea, discuss glucose monitoring with your clinician.
These are reference notes from published research and reported use, not advice for a person: discuss your own situation with your clinician.
Where the bofanglutide reports come from
The library rates the evidence on bofanglutide as moderate: animal studies plus some human data.
Of the library’s 7 research notes on bofanglutide, 6 rest on randomized trials and 1 on community reports.
So bofanglutide has controlled trials in people to set its listed effects against.
Questions people ask
What are the side effects of bofanglutide?
The side effects most commonly reported for bofanglutide are nausea, vomiting and diarrhea, among 4 the library lists; the library’s evidence on it includes controlled trials in people.
Do bofanglutide’s side effects come from human studies?
The library rates the evidence on bofanglutide as moderate, and the library’s evidence on it includes controlled trials in people.
Which bofanglutide side effects are its own?
None: each effect the library lists for bofanglutide is listed for at least one other metabolic & GLP-1 compound too.
Does bofanglutide interact with other medicines?
The library’s interaction note on bofanglutide begins: No interaction results have been published; Gan & Lee has run studies of its effect on stomach emptying and on other drugs (NCT07128888) and on metformin (NCT06670209).